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Summary Recurrence and survival rates were studied in 175 women with breast cancer who, until the
development of recurrent disease, received no treatment other than a modified radical (Patey) mastectomy,
and in whom the oestrogen (REc) and progesterone (RPc) receptor content of the primary tumour was
measured. At the time of first relapse most patients received endocrine therapy.
At a minimum follow-up of 58 months post menopausal patients who possessed REc had an increased
relapse-free survival (RFS) (P=0.02). When examined by node status patients with 1-3 axillary nodes
containing tumour also had an improvement in RFS (P=0.02). There was no benefit for node-negative or
premenopausal patients. In 163 patients in whom RPc was measured, RFS was unaffected by the possession
of this receptor regardless of the degree of node involvement or menopausal status.
Patients with REc had a significantly longer survival following mastectomy than patients without it
(P=0.006). This was most marked in post-menopausal (P=0.003) and node-positive (P=0.03) patients.
Survival following mastectomy was also increased in patients possessing RPc (P=0.04) and again was most
marked for post-menopausal patients (P=0.01), although no difference could be identified within node
subgroups.
There were significant differences in the post-relapse survival of REc and RPc positive and negative
patients (REc P=0.03, RPc P=0.001). Patients with both receptors survived -37 months longer than their
receptor-negative counterparts.
This study failed to confirm that the measurement of REc and RPc can reliably predict early relapse in
breast cancer. The greater overall survival of receptor-positive patients is mainly due to an increase in survival
following relapse. This may reflect the response of receptor-positive tumours to endocrine therapy given for
recurrent disease.
Several reports have suggested that early recurrence
of breast cancer is clearly associated with a lack of
either oestrogen receptors (REc) or progesterone
receptors (RPc) in the primary tumour (Allegra et
al., 1979; Cooke et al., 1979. Forrest et al., 1980;
Westerberg et al., 1980; Paterson et al., 1982;
Pichon et al., 1980; Mason et al., 1983; Clark et al.,
1983). However the evidence is conflicting and data
from other studies have failed to confirm the value
of either REc or RPc as a guide to prognosis, (Hilf
et al., 1980; Shapiro et al., 1982; Howat et al.,
1983; Allegra et al., 1979; Kinne et al., 1981;
Mason et al., 1983; Stewart et al., 1983).
By contrast there is general agreement that
patients with breast cancer whose tumours contain
REc survive longer after mastectomy than those
who do not have this receptor (Bishop et al., 1979;
Hahnel et al., 1979; Croton et al., 1981; Kinne et
al., 1981; Samaan et al., 1981; Von Maillot et al.,
1982; Mason et al., 1983; Stewart et al., 1983).
Although there are few data on the role of RPc and
survival, Mason and her colleagues (1983) reported
significant improvement for patients who were
RPc +ve. Whether the beneficial effect of the
presence of receptors on overall survival is the
result of a longer disease-free interval or a
prolongation of survival after relapse, or both, is
not clear, but it is now well established that
receptor containing tumours are more likely to
respond to endocrine therapy (Maass & Jonat,
1983), and it has been suggested that the
improvement in survival following mastectomy may
merely reflect the response to treatment given for
recurrent disease (Howat et al., 1982).
In this study we have sought to establish the role
of REc and RPc as prognostic indicators for both
recurrence and survival and to relate the results to
other factors known to affect the outcome in breast
cancer; the involvement of the axillary nodes by
tumour and the effect of endocrine therapy
following relapse.
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Materials and methods
Receptor assay
Oestrogen (REc) and progesterone (RPc) receptors
were measured in samples of histologically proven
primary tumours from women with breast cancer.
The Dextran-coated charcoal assay using [3H]
oestradiol or [3H]R5020 a synthetic progestin, has
been previously described (Barnes etal., 1977). Values
greater than 5fmolmg-1 for REc and 15fmolmg-1
for RPc of cytosol protein were regarded as
positive. Negative results from tumours where the
cytosol protein was less than 0.7mgml-1 were
excluded from the study.
Patients
One hundred and seventy five women with operable
disease (Tl-3 NO-1MO) were studied. Each had a
Patey modified radical mastectomy with a complete
dissection of the axilla. Patients with bilateral
tumours or distant metastases and those receiving
adjuvant endocrine or cytotoxic therapy, were
excluded from the study. After histological
examination of the axillary nodes, patients were
classified into three groups: those with no nodes
containing tumour; those with 1-3 nodes containing
tumour; and patients with 4 or more nodes
containing tumour.
Patients were examined one month after
operation, then every six weeks for 2 years,
thereafter annually. Local recurrence and nodal
disease was confirmed wherever possible by biopsy,
while bone or visceral metastases were established
on unequivocal radiological evidence.
Upon relapse local recurrence was treated by
excision alone or by excision and radiotherapy.
Most patients with distant metastases received













oophorectomy or X-ray menopause if pre-
menopausal.
Statistical methods
The steroid receptors were analyzed both as
qualitative and quantitative factors. For the study
of relapse free survival (RFS), overall survival and
post-relapse survival (PRS), time based curves were
computed by actuarial methods and compared by
the log-rank test (Peto et al., 1977). Comparison of
the different numbers of patients in subgroups was
done using the Chi-squared test for contingency
tables.
Results
Values for REc and RPc were available from 175
and 163 patients respectively.
Receptor status, node status and relapse-free survival
We have previously reported that at 15 months
after the last patient entered the study there was a
small but statistically significant increase in the
RFS of patients with REc compared to those
lacking it. This difference was no longer significant
when the minimum observation period reached 29
months (Howat et al., 1983). The most recent
analysis was carried out 58 months after the last
patient entered the study (maximum follow-up 88
months). Although there was still no statistical
difference in the overall RFS of patients with and
without REc when examined both qualitatively
(P=0.07) and quantitatively (P=0.2) (Figure IA),
when analysed with respect to menopause or node
status both post menopausal patients and those
with relatively few involved axillary nodes (1-3)
had an improved RFS if their tumours contained
Figure 1 Ostrogen receptor status of primary tumour and (a) Relapse-free survival (RFS); (b) Survival
following mastectomy; (c) Survival following first relapse (PRS).
I
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REc (P=0.02, P=0.02). No differences were seen
in any other subgroup.
The possession of RPc did not increase the RFS
during any period of follow-up (Figure 2A).
By contrast the presence of tumour invading the
axillary nodes had a profound detrimental effect on
RFS (P<0.0001). Seventy per cent of node+ve
patients had developed recurrent disease within
three years compared to 27% of patients whose
nodes were uninvolved (Figure 3A).
Receptor status, node status and survival after
mastectomy
Seventy-six patients of whom 22 were
premenopausal and 54 postmenopausal developed
recurrent disease. Of these 39/76 were REc+ve and
27/70 RPc+ve, (Table I). Two of them had no
further treatment and 13 had local treatment only.
Of those with disseminiated disease the majority,
89% (53/59) were given endocrine therapy at the
time of first relapse regardless of the receptor status
of the primary tumour (Table II). The remainder
were given cytotoxic agents only. One patient has
been lost to follow-up and one has died of
intercurrent illness. Fifty two women have died of
breast cancer.
Although there was a lack of any great effect of
steroid receptors on the RFS, there were significant
differences between patients with and without REc
and RPc when survival from mastectomy to death
was considered (REc P=0.006; RPc P=0.036)
(Figures. 1B, 2B). Patients with the highest values
of REc survived longest (P=0.01), but the benefit
for patients with RPc was unrelated to its value.
The improvement in the survival of receptor +ve
patients was most marked in those who were post-
























Figure 2 Progesterone receptor status of primary tumour and (a)































Figure 3 Node status and (a) Relapse-free survival (RFS); (b) Survival following mastectomy; (c) Survival
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Table I Details of 76 patients with recurrent disease.
NO NJ-3 N4+
REc+ve 39 18 7 14
Rec-ve 37 10 12 15
RPc+ve 27 8 7 12
RPc-ve 43 16 11 16
Rec status known in 76 patients.
RPc status known in 70 patients
Table II Treatment given at time of first relapse
REc+ ve REc-ve RPc+ve RPc-ve
R D R D R D R D
No further
treatment
2 (2)* 1 0 1 1 1 0 1 1
Local excision
XRT
13(13)* 8 2 5 4 8 5 5 1
Endocrine
Therapy
53 (51) 26 11 27 20 23 9 28 21
Chemotherapy
6 (4)* 4 2 2 2 1 1 3 2
R=Relapsed
D=Dead
*Numbers too few for analysis
Numbers in parenthesis are those
both REc and RPc data available.
patients for whom
were no significant differences for premenopausal
patients. Menopausal status per se did not influence
survival after mastectomy. Node+ve patients who
were also REc+ve survived longer than those who
were node +ve but REc-ve (P =0.03). However
there was no difference in the survival from
mastectomy of node+ve patients with or without
RPc. The effect of receptors on survival was
confirmed when REc and RPc were analysed
together. Patients who had both receptors fared
significantly better than those with neither. Those
who had a single receptor (REc+ve, RPc-ve and
REc-ve, RPc+ve) followed an intermediate course
(P=0.045). The node status had a distinct
predjudicial effect on the survival of patients
following mastectomy (P<0.0001) (Figure 3b).
However once relapse had occurred the influence of
the node status on survival was no longer apparent
and node-ve patients died at the same rate as
those who were node+ve (P=0.67) (Figure 3c).
Receptor status andpost-relapse survival
By contrast, following the development of
recurrent disease there were marked differences in
the post-relapse survival (PRS) of REc+ve and
RPc+ve patients compared with those who lacked
receptors (REc P=0.03; RPc P=0.001) (Figures Ic,
2c). Although numbers are small these differences
were most evident in RPc+ve postmenopausal
patients (Table III). When PRS was further
analysed in relation to receptor status and node
involvement, node+ve, receptor+ve patients lived
longer after relapse than node+ve receptor-ve
patients. Although there was a trend in favour of
increased survival for patients who had REc and
RPc in subgroups based on node status (NO,
NI -3, N4+) for most it did not reach statistical
significance. Only those patients who were RPc+ve
and node-ve lived significantly longer than their
receptor-ve counterparts (P=0.01). In this
subgroup of patients, all with recurrent disease, all
RPc+ve patients were alive whereas 10 RPc-ve
patients had died at the time ofanalysis.
Fifty percent of REc-ve patients with recurrent
disease were dead by 19 months, but it was not
until 48 months that 50% of REc+ve patients had
died. This suggests that the survival of REc+ve
patients after recurrence may be prolonged by - 29
months. The increase in PRS for RPc+ve patients
was 42 months. When REc and RPc were
considered together patients with both receptors
survived -37 months longer after relapse than
patients with neither (P=0.009). Five years after
mastectomy there was an 18% advantage in terms
of survival for those patients with both receptors.
Patients who received endocrine therapy for
recurrent disease and who had either REc or RPc
or both survived significantly longer than patients
with no receptors (REc+ve vs REc-ve, P=0.02;
RPc+ve vs RPc-ve, P=0.0003) (Figure 4). The
number of patients who received other forms of
treatment was too small to permit statistical
analysis.
Discussion
We have previously reported our observation that
possession of REc and RPc has little effect on the
overall RFS of women with operable breast cancer
(Howat et al., 1983). Data from a more prolonged
follow-up of the same patients presented here
largely confirms these earlier findings.
The evidence that possession of REc has a
beneficial effect on RFS is discordant. Some
workers have reported that a lack of receptor is
clearly associated with early recurrence of disease
(Knight et al., 1977; Maynard et al., 1978; AllegraHORMONE RECEPTORS AND SURVIVAL IN BREAST CANCER
Table III Results of univariate analysis
Relapse-free Survivalfrom Post-relapse
Survival mastectomy survival
P value to death P value P value
REc<5fmol vs>5fmolmg1 NS 0.006 0.03
REc value (0,5-30, 30-60fmolmg1 NS 0.01 *
RPc< 15fmol vs) 15fmolmg1 NS 0.036 0.001
RPc value (0,<100, >l00fmolmg1 NS NS *
REc/RPc combined NS 0.045 0.009
Premenopausal vs postmenopausal NS NS NS
REc +ve vs -ve, premenopausal NS NS NS
Rec +ve vs -ve, postmenopausal 0.02 0.03 NS (0.07)
RPc +ve vs -ve, premenopausal NS NS NS
RPc +ve vs -ve, postmenopausal NS 0.01 0.0001
Node status (NO, NI-3, N4+) 0.0001 0.0001 NS
REc +ve vs -ve, Node -ve NS NS NS
REc +ve vs -ve, Node +ve 0.01 0.03 NS
REc +ve vs -ve, N1-3 0.02 NS (0.056) NS
REc +ve vs-ve, N4+ NS NS NS
RPc +ve vs -ve, Node -ve NS NS 0.01
RPc +ve vs -ve, Node +ve NS NS 0.05
RPc +ve vs -ve, N1-3 NS NS NS
RPc +ve vs -ve, N4+ NS NS NS








Figure 4 Survival of receptor-positive and negative
patients treated by endocrine therapy for recurrent
breast cancer.
et al., 1979; Cooke et al., 1980), whereas others
have found that an increase in RFS for RE+ve
patients is present only in subgroups based on
menopausal and node status (Kinne et al., 1981;
Samaan et al., 1981). In this study an increase was
seen in the RFS of REc+ve patients with lymph
node involvement. This was most evident in those
with minimal disease (1-3 Nodes), suggesting that
any beneficial effect of REc on RFS is relatively
weak as it is seen neither in those patients with a
rapid rate of recurrence after mastectomy
(4+nodes) nor in those in whom the recurrence
rate is low (node-ve). Hilf et al., 1980; Shapiro et
al., 1982; Mason et al., 1983 and Stewart et al.,
1983 have found no difference in the RFS of
patients with and without REc. Other studies have
shown that an initial advantage in favour of
REc+ve patients disappears when follow-up
exceeds 5 years so that the recurrence rate becomes
the same for REc+ve and RE-ve patients
(Hiihnel, 1979; Von Maillot et al., 1982; Saez et al.,
1983).
Similarly there is conflicting evidence for a
relationship between RPc and RFS. Pichon et al.,
1980; Mason et al., 1983, and Saez et al., 1983,
have demonstrated that patients with RPc had a
longer disease-free survival than those without.
Clark's (1983) study would seem to confirm this
although two thirds of his patients had been treated
with adjuvant tamoxifen. Others, as in the present
study could not show a relationship between RPc
and RFS (Allegra et al., 1979; Kinne et al., 1981;
Stewart et al., 1983.) Von Maillot (1982) again
found that an early advantage for RPc+ve patients
disappeared as follow-up was prolonged.
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Why published results are so varied is not clear
but it has been shown that the predictive
capabilities of a receptor may be altered if the value
at which it is deemed positive is redefined (Forrest
et al., 1980; Mason et al., 1983).
There is more general agreement on the
relationship between steroid receptors and survival.
Most reports have shown that following
mastectomy patients with either REc or RPc or
both live longer than those who are receptor-ve
(Bishop et al., 1979; Hahnel et al., 1979; Kinne et
al., 1981; Croton et al., 1981; Godolphin et al.,
1981; Stewart et al., 1981; Paterson et al., 1982;
Von Maillot et al., 1982; Mason et al., 1983),
although Benson et al., 1982, reported that an
initial increase in overall survival for REc+ve
women was no longer apparent after 5 years. Our
own results confirm that women with one or both
receptors in the primary tumour have a significantly
improved survival after mastectomy and that
REc+ve RPc+ve patients live longest.
The results of many studies indicate that the REc
status of a primary tumour correlates well with the
response to any form of endocrine therapy given
for recurrent disease. REc+ve patients may show a
remission rate of 50-70%, whereas in REc-ve
patients the response rate may be as low as 3%
(Jensen, 1981; Stewart et al., 1982; Maass & Jonat,
1983). Most reports of an improved overall survival
for REc+ve patients have included women given
hormone therapy for advanced disease (Bishop et
al., 1979; Hahnel et al., 1979; Stewart et al., 1981;
Kinne et al., 1981; Croton et al., 1981; Godolphin
et al., 1981; Paterson et al., 1982; Mason et al.,
1983), but in not all of these papers has the effect
of receptors after relapse been considered. If it has
been discussed, it has been found, as in the present
study that REc+ve patients have a significantly
longer interval between recurrence and death than
do REc-ve patients (Hahnel et al., 1979; Kinne et
al., 1981; Paterson et al., 1982). This appears to be
related to the presence or absence of REc rather
than to its level (Stewart et al., 1981). Godolphin et
al., (1981) found the increase in PRS of REc+ve
patients to be significant only in those who had
received hormones after relapse.
Our results broadly agree with these studies and
seem to imply that any increase in survival after
mastectomy is chiefly due to the response of
receptor+ve patients to endocrine therapy given for
recurrent disease rather than to the intrinsic nature
of the tumour. Some support for this hypothesis
may be derived from our finding that post-
menopausal REc+ve and RPc+ve patients have
the longest overall survival and postmenopaus4l
RPc+ve patients the longest PRS. Stewart et al.
(1983) also found that overall survival was most
marked in some receptor+ve postmenopausal
patients. This may partly be explained by the
observations that absolute values of REc rise with
age (Skinner et al., 1980) and that high values of
REc are associated with an increased likelihood of
a beneficial response to endocrine therapy
(McGuire, 1978). In the present study those
patients with highest values of REc survived
longest.
As the presence of RPc is closely related to that
of REc it might be expected that the results of
analysis of the effect of these receptors on survival
would be similar. The lack of association between
the value of RPc and survival is not readily
explained.
The role of RPc in the management of advanced
breast cancer is less clearly defined than that of
REc but there is increasing evidence that RPc+ve
patients also respond more readily to hormones
and the response of REc+ve cancers is enhanced
by the presence of RPc (McGuire, 1978, Stewart et
al., 1982; Johnson et al., 1983). In this study PRS
was favourably influenced by RPc and again it
seems that it is largely the response to treatment of
recurrent disease that is reflected in the improved
overall survival.
RPc appears to influence PRS to a greater degree
than does REc. There were relatively few patients
in the study who were REc-ve RPc+ve (12%)
compared to those who were REc+ve, RPc-ve
(34%) and the majority of RPc+ve patients also
had REc (88%). As those with both receptors may
be expected to respond more readily to hormone
treatment (McGuire, 1978; Stewart et al., 1982) this
in time may be reflected by an increase in PRS for
RPc+ve patients when compared with those with
REc. However, after relapse the incidence of single
receptor positivity was similar for both REc and
RPc (28% and 22% respectively) and the apparent
superiority of RPc may merely result from the
relatively small numbers ofpatients involved.
There is some evidence to suggest that the
possession of receptors may influence the overall
survival in other ways. We have shown that the
RFS of postmenopausal and some node+ve
patients was increased if REc was present and Von
Maillot (1982) found improved overall survival for
both REc and RPc+ve patients in the absence of
any endocrine therapy. In addition Stewart et al
(1981) and Nicholson and his colleagues (1981)
have shown that the site of first distant metastasis
can be related to REc status. As the location of
metastasis correlates well both to the response to
therapy (Baum, 1980) and survival in advanced
breast cancer (Cutler, 1969), it may be that the
receptor status influences survival following relapse
only indirectly via the site of metastatic disease.
Although these observations suggest that steroid
receptors may be a biological factor exerting someHORMONE RECEPTORS AND SURVIVAL IN BREAST CANCER 269
influence throughout the course of breast cancer, in
our experience it seems that they have a negligible
effect on RFS and exert most of their influence
after relapse.
It is clear that patients without axillary node
involvement survive significantly longer than their
node+ve counterparts, but by contrast with the
receptor status, the increase in survival reflects a
longer RFS in those patients with earlier stages of
disease. The node status is unrelated to survival
once recurrent disease becomes evident. This
suggests that node status indicates the age of the
tumour at the time of diagnosis rather than
reflecting any intrinsic biological property. Hahnel
et. al. (1979) and Paterson et al. (1982) report
similar observations.
It has been proposed that as receptor-ve
patients fare badly, measurement of receptors may
be used to select those women who would benefit
from systemic adjuvant therapy following
mastectomy (Cooke et al., 1980; Godolphin et al.,
1981; Paterson et al., 1982). As the present study
fails to confirm that REc and RPc status can
reliably identify patients at risk of early relapse we
would doubt this policy, particularly with regard to
adjuvant chemotherapy. An accurate knowledge of
the axillary node status remains the pre-eminent
prognostic factor. The place of routine adjuvant
endocrine therapy in the management of operable
breast cancer has yet to be established. Preliminary
reports suggest that tamoxifen given after
mastectomy significantly delays recurrence in some
patients (Nolvadex Adjuvant Trial Organisation,
1983; Ribeiro & Palmer, 1983). Should the efficacy
of this form of treatment be confirmed, receptor
measurement, whilst failing to predict early relapse
in untreated patients may be of some value in
identifying those patients most likely to live longer
if given adjuvant endocrine therapy (Clark et al.,
1983).
We should like to thank Prof. R.A. Sellwood of the
University Hospital of South Manchester, for permission
to study patients in his care, Mrs E. Hayward for expert
technical assistance and Ms Janice Gormley for typing the
manuscript.
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